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Thiocoraline is a thiodepsipeptide, isolated from an actinomycete,
the Micromonospora marina, a microorganism collected off the
Mozambique coast (Perez Baz et al, 1997; Romero et al, 1997). It
has shown antiproliferative activity against human non-small cell
lung, breast, colon, renal and melanoma cancer cell type subpanels
in the National Cancer Institute in vitro screening program.
Subsequently, thiocoraline also exhibited anti-tumour activity in
vivo against human carcinoma xenografts (Faircloth et al, 1997).
The lack of information on the mechanism of the antiprolifera-
tive and anti-tumour activity of thiocoraline prompted us to
perform this study aimed at evaluating the cell cycle perturbations
induced by this novel drug in human cancer cell lines and eluci-
dating its biochemical mode of action.
MATERIALS AND METHODS
Cells and culture conditions
The human colon adenocarcinoma LoVo cell line was grown in
monolayer in Ham’s F12 medium supplemented with 10% fetal
calf serum, 1% vitamins (BME vitamin solution, 100´), 1% glut-
amine 200 mM (Gibco Europe, Paisley, UK) at 37°C in a humidi-
fied 5% carbon dioxide atmosphere in T25 cm2 tissue flasks
(IWAKI, Bibby Sterilin, Staffordshire, UK). The human colon
adenocarcinoma SW620 cell line was grown in monolayer in
RPMI-1640 medium supplemented with 10% fetal calf serum in
T25 cm2 tissue flasks.
Clonogenicity test
Thiocoraline (Figure 1) was kindly supplied by Pharma Mar (S.A.
Tres Cantos, Spain). The effect of the thiocoraline treatment on
LoVo and SW620 cells was evaluated by a standard clonogenic
assay. Exponentially growing cells were treated for 1, 6 or 24 h
with different concentrations of thiocoraline. After treatment, cells
were washed twice with phosphate buffered saline (PBS); 800
control and treated cells were plated in 30-mm Petri dishes with
3 ml fresh medium. Cell viability was checked using erythrosin B.
The colonies were allowed to develop for 10–14 days. Plating effi-
ciency of the exponentially growing control cells was between 50
and 60%. The colonies were stained with 1% crystal violet solu-
tion in 20% ethanol, and the number of colonies were measured
using the Entry Level image system (Immagini & Computer,
Bareggio, Milan, Italia). A background correction was made, and
the smallest control cell colony was taken as the minimum for
setting the cut-off point (Erba et al, 1994).
Bromodeoxyuridine incorporation
This protocol allowed us to study and compare the DNA synthesis
rate and labelling index (percentage of cells in synthetic phase that
are labelled with bromodeoxyuridine (BrdU)) at different times
after thiocoraline treatment and drug-washout. Exponentially
growing LoVo and SW620 cells were treated for 24 h with 0.5 mM
thiocoraline, which caused 30–40% growh inhibition at 24 h after
drug-washout. After treatment, the drug-containing medium was
removed, cells were washed twice with PBS and fresh medium
was provided. During the last 15 min drug treatment, and at 24, 48
and 72 h after drug-washout, 20 mM BrdU was added to the cells,
then the cells were directly fixed in 70% ethanol.
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With this protocol it was possible to obtain a distinct evaluation of
the cell cycle perturbations in cells that were in S phase (BrdU-
positive cells) or in G1 or in G2/M phases (BrdU-negative cells)
when thiocoraline treatment started. Exponentially growing cells
were treated for 15 min with 20 mM BrdU. At the end of BrdU
incubation the medium was removed, cells were washed twice
with PBS and treated for 24 h with 0.5 mM thiocoraline. After
treatment the drug-containing medium was removed, the cells
were washed twice with PBS and fresh medium was provided. At
0, 4, 8, 12 and 24 h during drug treatment, and 4, 8, 12, 24 h after
drug-washout, control and treated cells were fixed in 70% ethanol
and kept at 4°C before staining.
BrdU/DNA staining
For detection of BrdU incorporation into DNA, the fixed cells
were washed with cold PBS and the DNA was denatured with 1 ml
of 3 N hydrochloric acid for 20 min at room temperature to allow
the anti-BrdU monoclonal antibody (mAb) to react with the BrdU
incorporated in the DNA chain. DNA denaturation was stopped by
adding 3 ml of 0.1 M sodium tetraborate pH 8.5. After centrifuga-
tion, the pellet was incubated with 1 ml of 0.5% Tween-20 (Sigma
Chemicals Co., St Louis, MO, USA) in PBS and 1% normal goat
serum (NGS) (Dakopatts, Denmark) for 15 min at room tempera-
ture. The incorporated BrdU was visualized by incubating the
cells with the mAb anti-BrdU (Becton Dickinson, Sunnyvale, CA,
USA) diluted 1:10 in 0.5% Tween-20 in PBS for 1 h at room
temperature in the dark. After centrifugation, the pellet was
incubated with 1 ml of 0.5% Tween-20 and 1% NGS for 15 min
at room temperature. Then the cells were incubated with a
fluorescein isothiocyanate (FITC)-conjugated affinipure F(ab¢)2
fragment goat anti-mouse IgG (Jackson Immuno Research
Laboratories Inc, USA) diluted 1:50 in 0.5% Tween-20 in PBS for
1 h at room temperature in the dark. The cells were finally resus-
pended in 2 ml of a solution containing 2.5 mg ml–1 of propidium
iodide (PI) in PBS and 25 ml RNAase 1 mg ml–1 in water, and
stained overnight at 4°C in the dark. Monoparametric DNA and
biparametric BrdU/DNA analysis was performed on at least
20 000 cells for each sample by the FacSort system (Becton
Dickinson). The data are the average of three replications and
were analysed with the Cell Quest software. The fluorescence
pulses were detected using a band pass filter 530 ± 30 nm and
620 ± 35 nm, for green and red fluorescence respectively, in
combination with a dichroic mirror 570 nm (Erba et al, 1995). The
percentage of the cell cycle phase distribution were calculated by
the method of Krishan and Frei (Krishan and Frei, 1976).
Cyclin D1/DNA staining
At the end of treatment, and at different time intervals after drug
washout, the cells were fixed in 1% formaldehyde and stored at
4°C. The fixed cells were washed in cold PBS and permeabilized
with 0.25% Triton X-100 (Sigma, St Louis, MO, USA) in PBS
for 5 min in ice. Then they were washed in PBS and incubated
with 200 ml of mAb anti-human cyclin D1, G124-326 clone
(Pharmingen, San Diego, CA, USA), at the concentration of
2.5 mg ml–1 in PBS + 1% NGS overnight at 4°C in the dark. A
blank sample was prepared by incubation of cells with 200 ml of
1% NGS in PBS, or with the isotype IgG instead of the cyclin.
972 E Erba et al
British Journal of Cancer (1999) 80(7), 971–980 © 1999 Cancer Research Campaign 
OH
H
I
N
N
O CO
NH
O
SCH3
N
S
CO
N CH3
CO
N-CH3
CH3 S
O
N
H
H N
S
O
N
OH
CO
CO
CO
N-CH3
S
S
CH3
Figure 1 Thiocoraline chemical structure
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Figure 2 Effect of thiocoraline on the clonogenicity of LoVo and SW620 cells. Clonogenic potential of exponentially growing untreated cells ranged between
50 and 60% of the cells plated, which was normalized to 100%. Each point is the mean of six replicates; bar, standard error of the mean. (l) = 1 h treatment;
(l l) = 6 h treatment; (n) = 24 h treatment. (A) LoVo cells; (B) SW620 cellsAfter removing the cyclin D1, the cells were incubated with 200 ml
of FITC-conjugated affinipure F(ab¢)2 fragment goat anti-mouse
IgG diluted 1:50 in 0.5% Tween-20 in PBS for 1 h at room temper-
ature in the dark. The cells were finally resuspended in 2 ml of a
solution containing 2.5 mg ml–1 PI in PBS and 25 ml RNAase 1 mg
ml–1 in water, and stained overnight at 4°C in the dark (Faretta et
al, 1998).
Alkaline elution
LoVo and SW620 cells were labelled for 24 h using medium supple-
mented with 0.5 mCi ml–1 3H-TdR (Amersham, specific activity
85 Ci mmol–1) and exposed to different concentrations of thiocoraline
for 24 h. Then the cells were kept in ice, washed with PBS and
layered on polycarbonate filters, 2-mm pore size and 25-mm diameter
Thiocoraline, a novel inhibitor of DNA synthesis 973
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Figure 3 Effects of thiocoraline on the cell cycle phase distribution of LoVo cells, 0, 4, 8, 12 and 24 h during drug treatment, and 4, 8, 12 and 24 h after
drug-washout. Upper panel: (A) Biparametric BrdU/DNA analysis of control cells. (B) Biparametric BrdU/DNA analysis of thiocoraline-treated cells. Lower
panel: (A) DNA histograms of control cells (whole population). (B) DNA histograms of thiocoraline-treated cells (whole population). (C) DNA histograms of
BrdU-negative control cells. (D) DNA histograms of BrdU-negative thiocoraline-treated cells. (E) DNA histograms of BrdU-positive control cells. (F) DNA
histograms of BrdU-positive thiocoraline-treated cells(Nucleopore, Costar). Cells (106 cells per sample) were lysed with
5 ml of a lysis solution containing 2% sodium dodecyl sulphate
(SDS), 0.02 M EDTA, 0.1 M glycine (pH 10), which was allowed to
flow through the filter by gravity. After connecting the outlet of the
filter holders to the pumping system, 2 ml of the lysis solution
containing 0.5 mg ml–1 proteinase K (Merk) were added to the reser-
voir over the polycarbonate filters. DNA was eluted from the filters
with a solution containing 20 mM EDTA, 0.1% SDS and adjusted to
pH 12.2 with tetrapropylammonium hydroxide (Fluka). Three-, 6-,
9-, 12- and 15-h fractions were collected, and fraction and filters
were processed as previously described (Kohn et al, 1981).
DNA unwinding assay
The assay was performed by using a 20 ml final reaction volume
containing supercoiled PUC18 DNA, 50 mM Tris, pH 8, 120 mM
potassium chloride (KCl), 10 mM-magnesium chloride (MgCl2),  0.5
mM adenosine 5¢-triphosphate (ATP), 0.5 mM dithiothreitol (DTT),
30 mg ml–1 nuclease free bovine serum albumin (BSA), different
concentrations of thiocoraline and 2 units of human type II topoiso-
merase (topoGEN). As positive control we used 125 mM m-AMSA
(purchased from Sigma). Reactions were performed at 37°C for
30 min and stopped by addition of stop buffer (5% sarcosyl,
0.0025% bromophenol blue, 25% glycerol). Gel analysis was
performed on 1.5% agarose gel. Gel was stained with ethidium
bromide, washed with distilled water and photographed under UV
light.
Cleavable complex formation
The assay was performed as described by Poddevin et al (1993),
with slight modification. Briefly, a 30 ml final reaction volume
containing 25 ng of 5¢-end 32P-labelled SV40 DNA (HpaII, BanI),
10 mM Tris, pH 7.5, 50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA,
0.5 mM DTT, 1 mM ATP, 3 units of human topoGEN, different
concentrations of thiocoraline were used. As positive control we
used 0.5 mM doxorubicin (kindly donated by Dr Suarato, Pharmacia
Upjohn). Reactions were performed at 37°C for 30 min and stopped
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Figure 3 cont.by addition of 3 ml of SDS 10% and 3 ml of proteinase K 5 mg ml–1,
followed by incubation for 40 min at 42°C. After phenol–cloroform
extraction 6 ml of loading buffer (5% sarkosyl, 0.0025% bromo-
phenol blue, 25% glycerol) were added to each sample before
loading onto 1% agarose gel made in 1 ´ Tris–borate–EDTA buffer
plus 0.1% SDS. Gel was dried and autoradiographed for 12 h.
DNA polymerase assay
Human DNA polymerase a was purified from acute lymphoblastic
leukaemia CCRF-CEM cells by immunoaffinity chromatography
(Catapano et al, 1993). Two oligodeoxyribonucleotides, the 11-mer
5¢-GAATTCAGATC-3¢ and the 25-mer 5¢-GCGGTGACCCGGGA-
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Figure 4 Effects of thiocoraline on the cell cycle phase distribution of SW620 cells, 0, 6, 15 and 24 h during drug treatment, and 8, 24, 39 and 48 h after
drug-washout. Upper panel: (A) Biparametric BrdU/DNA analysis of control cells. (B) Biparametric BrdU/DNA analysis of thiocoraline-treated cells. Lower
panel: (A) DNA histograms of control cells (whole population). (B) DNA histograms of thiocoraline-treated cells (whole population). (C) DNA histograms
of BrdU-negative control cells. (D) DNA histograms of BrdU-negative thiocoraline-treated cells. (E) DNA histograms of BrdU-positive control cells. (F) DNA
histograms of BrdU-positive thiocoraline-treated cellsGATCTGAATTC-3¢, were synthesized. Prior to the primer extension
assay, the 11-mer and 25-mer were annealed by heating at 90°C for 5
min followed by cooling to room temperature over a period of 1 h.
Primer extension reactions (10 ml) contained 1 mM of the annealed
11- and 25-mers, 0.75 units of DNA polymerase a, 10 mM dNTPs
with 1 mCi of [a-32P]dCP (20 000 dpm pmol–1), 10 mM MgCl2,
100 mg ml–1 of BSA, 1 mM DTT, 50 mM Tris–HCl pH 7.5, and the
indicated concentrations of either dimethyl sulphoxide (DMSO) or
thiocoraline. The samples were incubated for 60 min at 37°C. The
reactions were then stopped by addition of EDTA and loading
buffered, and electrophoresed in a denaturating 20% polyacrylamide
gel as previously described. The products of the primer extension
reactions were measured by scanning the gel with a phosphoimager
and analysing the digitized images with the ImageQuant software
(Molecular Dynamics). The counts measured in a sample lacking the
enzyme (Figure 9, lane 8) were subtracted from the radioactivity
measured in the complete reactions. The results were expressed as
percentage of products synthesized in the presence of thiocoraline
compared to the control reaction lacking both DMSO and thiocora-
line (Figure 10, lane 1).
RESULTS
Figure 2 shows the clonogenic inhibitory effect of thiocoraline on
LoVo (Figure 2A) and SW620 cells (Figure 2B). Exposure for 1 or
6 h with thiocoraline did not cause a significant inhibition in the
clonogenicity of SW620 and LoVo cells. However, a 24 h expo-
sure to thiocoraline resulted in a much higher cytotoxicity on both
cell lines. SW620 cells were more sensitive to thiocoraline than
LoVo cells, with an IC50 of 15 nM and 500 nM respectively.
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Figure 4 cont.The cell cycle phase perturbations induced by thiocoraline on
LoVo and SW620 cells were investigated by monoparametric flow
cytometric DNA analysis after 24 h treatment and at 24 h after drug-
washout. By using PI staining, the effects of thiocoraline on the cell
cycle phase distribution was not evident, since the DNA histograms
of thiocoraline-treated cells were similar to the controls (data not
shown). For this reason, we performed a biparametric flow cyto-
metric BrdU/DNA analysis to evaluate the effect of thiocoraline
exposure on cell cycle phase distributions, considered separately the
BrdU+ (S phase) and the BrdU – (G1 or G2/M phases) cells. Figures
3 and 4 show the effects on the cell cycle phase distributions caused
by thiocoraline on LoVo (Figure 3) and on SW620 cell line (Figure
4) during drug treatment and after drug-washout, evaluated using
the biparametric BrdU/DNA analysis. The upper panel shows the
biparametric analysis of BrdU and DNA content, while the lower
panel separately shows the DNA histograms of the whole popula-
tion (A and B), the DNA histograms of the BrdU – (C and D) and
the BrdU+ cells (E and F). The thiocoraline-induced cell cycle
perturbations were similar in LoVo and SW620 cell lines.
Thiocoraline was found to prevent those cells that were in G1 when
drug treatment started (BrdU – cells) from entering S phase. At 24 h
drug treatment BrdU – SW620 cells were still completely blocked in
G1 phase, whereas a small fraction of BrdU – LoVo cells progressed
to S-late G2/M phases.
The BrdU+ cells, those cells which were in S phase when thio-
coraline treatment started, were delayed in their progression from
the S phase into the G2/M phase. Between 8 and 24 h for LoVo,
and between 15 and 24 h for the SW620 cell line the BrdU+ thio-
coraline-treated cells remained accumulated in the S and the G2/M
phases, while the control cells have started a new cell cycle (G1
Thiocoraline, a novel inhibitor of DNA synthesis 977
British Journal of Cancer (1999) 80(7), 971–980 © 1999 Cancer Research Campaign 
2
0
0
4
0
0
6
0
0
8
0
0
1
0
0
0
2
0
0
4
0
0
6
0
0
8
0
0
1
0
0
0
200 400 600 200 400 600
C
y
c
l
i
n
 
D
1
 
e
x
p
r
e
s
s
i
o
n
A B
C D
DNA content
Figure 5 Biparametric cyclin D1/DNA flow cytometric analysis of LoVo cells
treated with 0.5 mM thiocoraline evaluated at 24 h drug treatment (A, control
cells; B, thiocoraline-treated cells) and at 24 h after drug-washout (C, control
cells; D, thiocoraline-treated cells)
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Figure 6 Effects on DNA synthesis caused by thiocoraline exposure on
LoVo and SW620 cells evaluated by BrdU/DNA analysis. During the last
15 min thiocoraline treatment, and at 24, 48 and 72 h after drug-washout,
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Figure 7 Formation of DNA breaks on LoVo and SW620 cells exposed to
different concentrations of thiocoraline for 24 h. (A) LoVo cells; (B) SW620
cells. (n) = control cells; (s) = control cells irradiated at the dose of 150 rads;
(l) = 0.5 mM thiocoraline; (u u) = 1 mM thiocoraline; (s s) = 5 mM thiocoralineBrdU+ cells). At 24 h after drug-washout, the BrdU+ and
BrdU – LoVo cells started to cycle again, while the SW620 cells
did not reverse their thiocoraline-induced cell cycle perturbations.
A biparametric cyclin D1/DNA analysis was then performed to
characterize the cell cycle phase perturbations induced by thioco-
raline more precisely. Figure 5 shows the levels of cyclin D1 in
LoVo cells after 24 h thiocoraline treatment and after drug-
washout. The level of cyclin D1 was not changed as compared to
control cells, thus excluding the possibility that the slow progres-
sion of thiocoraline-treated cells through the cell cycle phase was
due to changes in the level of this cyclin. The level of cyclin D1
increased at 24 h after drug-washout when the cells moved from
G1 to S phase of the cell cycle. Similar increase in cyclin D1 level
was obtained also on SW620 cells. Furthermore, thiocoraline did
not cause an inhibition of cyclin D1-associated kinase activity
(data not shown).
Figure 6 shows the effects on DNA synthesis caused by thio-
coraline exposure. Thiocoraline did not cause a decrease in the
fraction of LoVo cells in the S phase of the cell cycle, while their
capacity to synthesize DNA was almost completely arrested after
24 h treatment and up to 48 h drug-washout. In SW620 cells, thio-
coraline caused nearly a 50% decrease in the number of cells in the
S phase of the cell cycle. Their capacity to synthetize DNA was
reduced and this effect was evident after 24 h treatment and up to
48 h drug-washout.
Figure 7 shows the results of the experiment performed to eval-
uate if thiocoraline was able to cause DNA breaks on LoVo and on
SW620 cells by using the alkaline elution method. DNA of thio-
coraline-treated cells was almost completely retained on filter like
the DNA of drug-untreated cells, whereas, as expected, a large
fraction of DNA of irradiated cells was eluted through the filter.
These results indicate that 24 h thiocoraline treatment did not
cause detectable DNA breaks at the concentrations that inhibited
growth rate of 50%.
Using topoGen unwinding assay we evaluated the inhibition of
topoGen catalytic activity by thiocoraline. As shown in Figure 8,
supercoiled PUC18 DNA (lane 1) was relaxed by Topoisomerase II
in the absence (lane 2) or presence of 50, 10 and 1 mM thiocoraline
(lanes 3, 4 and 5 respectively). Plasmid was also incubated with the
same concentrations of thiocoraline in the absence of Topoisomerase
II (lanes 7, 8 and 9). With thiocoraline we obtained the same results,
in terms of DNA unwinding, both in presence or absence of topoGen
enzyme (compare lanes 3 and 4 with 7 and 8). A concentration of 1
mM thiocoraline seemed to be ineffective to exert DNA relaxation in
absence of topoGen. In the presence of Topoisomerase II, m-AMSA,
used as a positive control, caused DNA unwinding (lanes 6).
These results would indicate that thiocoraline is not acting as a
Topoisomerase II inhibitor. Its ability to cause unwinding of DNA
is likely due to its binding to DNA, as already reported for several
intercalating agents. Several DNA topoisomerase inhibitors have
been reported to act as trapping cleavable complexes formed
between the enzyme and the DNA. Stabilization of the cleavable
complex results in single- or double-stranded DNA cleavage,
which can be assessed by using a sensitive technique based on the
detection of drug-induced DNA double-strand breaks in linearized
5¢-end 32P-labelled SV40 DNA. Figure 9 shows that a pattern of
cleavage sites can be observed on the labelled DNA incubated
with Topoisomerase II (compare lanes 1 and 2) and this pattern
was not altered when thiocoraline was added to the reaction
mixture at concentrations of 0.5 and 1 mM (lanes 4 and 5).
Doxorubicin, a known DNA Topoisomerase II inhibitor, was used
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Figure 8 DNA unwinding assay. Supercoiled pUC18 DNA was incubated
with 50, 10 and 1 mM thiocoraline in absence, or in presence, of 2 units of
human topoisomerase II, as described in Materials and Methods. As positive
control we used 125 mM m-AMSA
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Figure 9 Cleavable complex formation. 5¢-end 32P-labelled SV40 DNA was
incubated with 0.5 or 1 mM thiocoraline in presence of 3 units of human
topoisomerase II (Topo II), as described in Materials and Methods. As
positive control we used 0.5 mM doxorubicin (Doxo)
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Figure 10 Effects of thiocoraline treatment on the DNA polymerase a
activity. (A) Sequence of the 11-mer primer and 25-mer template DNA used
in the polymerase assay. (B) Autoradiography of a denaturating
polyacrylamide gel. Primer extension reactions containing various
concentrations of thiocoraline were incubated at 37°C for 60 min,
denaturated by heating at 90°C for 5 min, and then loaded on the 20%
polyacrylamide gel. Complete reaction (lane 1) contained 0.75 units of DNA
polymerase a, 1 mM of primer/template, 10 mM dNTPs and 1 mCi of
(a- 32P)dCTP. Samples in lanes 2–7 had the following additions: lane 2,
0.001% DMSO; lane 3, 0.01% DMSO; lane 4, 0.01 mM thiocoraline and
0.0001% DMSO; lane 5, 0.05 mM thiocoraline and 0.005% DMSO;
lane 6, 0.1 mM thiocoraline and 0.001% DMSO; lane 7, 1 mM thiocoraline and
0.01% DMSO. The sample in lane 8 had all the components of the complete
reaction minus the enzyme. Numbers to the left of lane 1 indicate the size in
nucleotides of the corresponding primer extension productsas positive control. 0.5 mM doxorubicin was able to induce topoGen-
mediated cleavage, as shown in Figure 9 (lane 3). These results
show that thiocoraline does not act as a DNA topoGen inhibitor.
The effects of thiocoraline on DNA polymerase activity were
evaluated using the DNA primer extension assay (Figure 10). In
this assay, DNA polymerase a catalysed the polymerization of
dNTPs onto an 11-mer DNA primer annealed to a 25-mer template
(Figure 10A). In the absence of the inhibitor, DNA polymerase a
produced a ladder of DNA fragments from 13 to 25 nucleotides in
length (Figure 10B, lane 1). The 13-mer was the shortest product
detected by autoradiography since the first radiolabelled dCMP
residue was incorporated opposite the guanine at position 13 in the
template. The addition of concentrations of DMSO (0.001 and
0.01% in lanes 2 and 3 respectively), similar to those present in the
samples containing thiocoraline, did not affect DNA polymerase a
activity. Primer extension was greatly inhibited in the presence of
concentrations of thiocoraline from 0.01 to 1 mM (Figure 10B,
lanes 4–7). The total amount of extended primers (i.e. all the prod-
ucts ³ 13 nucleotides long) was reduced more than 60 and 80% by
0.01 and 0.1 mM of thiocoraline respectively. We also analysed the
effects of thiocoraline on the synthesis of products that were either
< 20 or ³ 20 nucleotides long using the ImageQuant software. This
analysis indicated that the synthesis of products ³ 20 nucleotides
long was almost completely inhibited by thiocoraline (83 and 93%
inhibition with 0.01 and 0.1 mM). By contrast, the synthesis of the
products < 20 nucleotides long was inhibited only 45 and 57% by
0.01 and 0.1 mM thiocoraline respectively. This may reflect a pref-
erential inhibition of the elongation phase of the primer extension
reaction by thiocoraline as opposed to inhibition of the initial
stages of the reaction (e.g. initial binding of the enzyme or poly-
merization of the first dNTP).
DISCUSSION
The present study shows that the novel anti-tumour drug thio-
coraline, derived from the actinomycete Micromonospora marina,
blocks cell proliferation by arresting the cells in the G1 phase of
the cell cycle and decreasing the rate of S phase progression
towards G2/M phases. By looking at the cell cycle perturbation by
monoparametric DNA flow cytometric analysis, these effects of
thiocoraline would have been missed as the block of flow of cells
from G1 to S phase was compensated by the longer permanence of
cells in the S phase. Instead, using biparametric flow cytometric
analysis, it became evident that cells in the G1 phase during treat-
ment remained in G1, and cells in the S phase progressed much
more slowly than the control cells.
Data obtained at the National Cancer Institute showed that thio-
coraline growth inhibition and cytotoxicity compares well to some
other antibiotics of terrestrial origin, such as anthracyclines (e.g.
daunomycin, doxorubicin). Since the mechanism of cytotoxicity
of anthracyclines appears related to their ability to poison DNA
Topoisomerase II enzyme we hypothesized that thiocoraline could
act by the same mechanism of action and cause DNA breakage
(Pommier et al, 1985; Capranico et al, 1990). However, thiocora-
line did not inhibit DNA Topoisomerase II catalytic activity nor
did it stimulate topoisomerase-mediated DNA cleavage in vitro. It
could be argued that, in cells, the drug is metabolized to a species
able to inhibit DNA Topoisomerase II. However, this was not the
case, as no DNA breakage was observed in cells exposed to active
thiocoraline concentrations. The good correlation existing between
the pattern of sensitivity of the various cell lines in the National
Institute of Health drug screen to thiocoraline and doxorubicin
may be due to a common transport mechanism. Both doxorubicin
and thiocoraline are good substrates for P-glycoprotein. That is,
cells that were resistant to doxorubicin because of high expression
of P-glycoprotein are also resistant to thiocoraline (unpublished
data from this laboratory).
The cell cycle perturbations observed in cancer cells exposed to
thiocoraline suggest that the drug might act by inhibiting DNA
replication. Indeed, inhibition of BrdU incorporation into DNA
was observed following a 24 h exposure of both LoVo and SW620
cells to thiocoraline and up to 24–48 h after drug-washout. This
potent inhibitory effect of thiocoraline could be explained, at least
in part, by the ability of the drug to directly inhibit DNA poly-
merase a activity. Primer extension by purified DNA polymerase
a was almost completely inhibited by thiocoraline at concentra-
tions that inhibited both in vitro DNA synthesis and clonogenicity.
These results suggested that DNA polymerase a might be an
important intracellular target for thiocoraline, although we cannot
rule out that other DNA, or RNA, modifiying enzymes might also
be inhibited by thiocoraline in the cells. In addition, the prolonged
inhibition of DNA synthesis observed both in LoVo and SW620
cells following removal of the drug could be due to either persis-
tence of active drug concentrations in the cells or to the induction
of secondary lesions that impaired the ability of the cells to repli-
cate DNA. Regarding the mechanism of inhibition of DNA poly-
merase a activity by thiocoraline, we can only speculate at present
that thiocoraline may act in ways similar to other natural products
(e.g. aphidicolin) that inhibit various DNA polymerases but are
not structurally related to nucleoside analogues. Thiocoraline may
prevent the elongation of the primers to full-length products by
interacting with either the enzyme or the primer/template complex
(Huberman, 1981). The predominant inhibition of the synthesis of
full-length products as compared to the initiation of the primer
extension reaction favour this hypothesis. This premature termina-
tion of primer extension may be due to thiocoraline-induced disso-
ciation of DNA polymerase a from the elongating primer/template
or, alternatively, ‘trapping’ the enzyme, presumably due to the
formation of an enzyme–thiocoraline–DNA ternary complex. The
latter mechanism has been proposed to explain aphidicolin-
induced inhibition of DNA synthesis (Sheaff et al, 1991).
Further biochemical studies will be required to provide precise
answers to these questions regarding the mechanism of inhibition
of DNA polymerase activity by thiocoraline.
In theory, one could expect that a DNA synthesis inhibitor
would not be very selective and would be similarly toxic against
all proliferating cells. Instead, the thiocoraline concentration
required to reduce the clonogenicity of SW620 cells to 50% of
normal was approximately 35 times less than that required to
inhibit clonogenicity of LoVo cells. These two cell lines grow at
approximately the same rate, and neither LoVo nor SW620 cells
express P-glycoprotein. However, they possess many biological
differences, which may affect their response to thiocoraline. For
example, LoVo cells express wild-type p53, whereas SW620 cells
express mutated p53. As shown by biparametric flow cytometric
analysis, thiocoraline induced similar cell cycle perturbations in
SW620 and LoVo cells. However, a different behaviour of these
two cell lines was observed following drug-washout. The G1
arrest and S phase delay were rather transient in LoVo cells, which
apparently recovered within 24 h post drug incubation. In contrast,
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prolonged in SW620 cells, which show very little recovery even at
48 h post drug incubation. Therefore, the greater sensitivity of
SW620 cells to thiocoraline was related apparently to a reduced
ability of these cells to bypass the G1 and/or S phase arrest and
recover from the thiocoraline-induced stress. The differential
sensitivity observed in these cell lines suggests that thiocoraline is
not a non-specific poison of all proliferating cells and may instead
be selectively toxic for cells with some specific, but yet unknown,
biological features. The determinants of the cellular sensitivity to
thiocoraline and the possible role of specific genetic alterations,
such as p53 mutations, are currently being investigated.
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